Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CVM vs OVID: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–3 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: CVM 1 – 4 OVID (1 Tie) Matrix Metrics: CVM 3 – 6 OVID

As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas OVID carries 44.9/100 (HOLD) at $2.58 (1.8x Forward P/E, -4693.7% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. OVID 44.9/100 HOLD), OVID captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-4693.7% vs. 0.0% operating margin) and revenue trajectory (-88.3% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile OVID trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CVM vs OVID
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.58
+1.38% 1D
Market Cap $462.6M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 0.92β · 97% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 52.5 · SMA20: $2.52 · SMA50: $2.50

6-Pillar Scorecard Institutional Category Breakdown (CVM 1 – 4 OVID)

Columns: Metric · CVM · OVID
1. Valuation Multiples OVID
Forward P/E 23.0x 1.8x
Trailing P/E 23.0x 1.8x
PEG Ratio 1.12x N/M
EV / Revenue N/M N/M
2. Growth & Scale CVM
Revenue Growth (YoY) -62.7% -88.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $28,558 $1.5M
Market Cap $20.9M $462.6M
3. Profitability & Quality OVID
Gross Margin N/A 100.0%
Operating Margin 0.0% -4693.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -252.5% -35.4%
4. Balance Sheet & Cash Flow OVID
Cash Generation (TTM) -$17M -$58M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.6M Net Debt (1.24x D/E) $1.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OVID
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile N/A (N/A) 145.7% (34th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CVM (3) vs OVID (6)
Institutional Metric CVM OVID Criterion Row Edge
Market Capitalization
Scale
$20.9M $462.6M Larger Scale OVID
Trailing P/E Ratio
Valuation
23.0x 1.8x Lower Multiple OVID
Forward P/E Ratio
Valuation
23.0x 1.8x Lower Multiple OVID
Revenue Growth (YoY)
Growth
-62.7% -88.3% Higher Growth CVM
Operating Margin (TTM)
Profitability
0.0% -4693.7% Higher Margin CVM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-252.5% -35.4% Higher ROE OVID
52-Week Range Position
Momentum
10% ($1–$8) 72% ($1–$3) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
0.65β · 120% Vol 0.92β · 97% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
56.6 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$28,558 $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.12x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($6.6M Net Debt (1.24x D/E)) -$58M ($1.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OVID +30.94 pp
CVM: -11.17% · OVID: +19.77%
3M Horizon CVM +9.33 pp
CVM: +0.0% · OVID: -9.33%
6M Horizon OVID +14.41 pp
CVM: -7.56% · OVID: +6.85%
1Y Horizon OVID +173.3 pp
CVM: -75.98% · OVID: +97.32%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CVM Revenue OVID Revenue CVM Op. Margin OVID Op. Margin Margin Leader
FY2013 $0M N/A -12450.1% N/A CVM
FY2014 $0M N/A -9721.4% N/A CVM
FY2020 N/A $10M N/A -645.4% OVID
FY2021 N/A $210M N/A 59.6% OVID
FY2022 N/A $0M N/A -3696.4% OVID
FY2023 N/A $0M N/A -15122.7% OVID
FY2024 N/A $0M N/A -10933.7% OVID
FY2025 N/A $10M N/A -585.2% OVID

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OVID CONSOLIDATION
150d in phase · OBV NEUTRAL
Current IV 145.7%
IV Percentile 34th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $462.6M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CVM vs OVID Key Questions & Quantitative Answers

As of Nov 16, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CVM carries a Unified Composite Score of 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin), whereas OVID carries 44.9/100 (HOLD) at $2.58 (1.8x Forward P/E, -4693.7% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. OVID 44.9/100 HOLD), OVID captures the overall institutional head-to-head verdict (6–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-4693.7% vs. 0.0% operating margin) and revenue trajectory (-88.3% vs. -62.7% YoY). Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile OVID trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CVM leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), CVM cumulative revenue shifted N/A while OVID shifted +0.0%. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.

OVID screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus OVID (-35.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, OVID carries 145.7% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.